CSI Market
Sign In | Register

An2 Therapeutics Inc (ANTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ANTX Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in An2 Therapeutics Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-18.21
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation2.43
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Noncash Operating Lease Expense-
Increase Decrease In Accrued Compensation-1.81
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-1.40
Increase (Decrease) in Accrued Liabilities-0.39
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.45
Other Working Capital-0.45
Other Noncash Income (Expense)0.00
Other net0.18
Payments for (Proceeds from) Other Operating Activities-0.77
Discontinued operations0.00
Net Cash flow from Operating Activities-19.07
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments4.63
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities4.63
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.12
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net38.70
Repurchase Of Early Exercised Stock Options-
Proceeds From Issuance Of Redeemable Convertible Preferred Stock Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock From The Underwritten Offering Net Of Commissions And Offering Expenses-
Proceeds From Issuance Of Common Stock From At The Market Offering Net Of Commissions And Offering Expenses-
Proceeds From Issuance Of Common Stock In Private Placement Net Of Issuance Costs21.89
Proceeds From Issuance Of Pre- Funded Warrants Net Of Issuance Costs15.37
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities38.82
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-19.07
Total Cash Flow24.38
4 historic quarters locked

Sign in to unlock the full An2 Therapeutics Inc cash flow history.

Sign In Create Free Account

About An2 Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-344569

Figures are derived from filed reports and may be restated. Historical data is subject to revision.